<p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Coagulation dysfunction and microvascular and macrovascular thrombotic events are common features of patients with acute COVID-19 in the early stages of the pandemic. Over the past four years, the incidence and manifestations of COVID-19-associated coagulopathy have evolved as a result of immunity acquired through natural infection and vaccination and the emergence of new SARS-CoV-2 variants. Therefore, there is a need to reevaluate diagnostic criteria and management strategies for COVID-19-associated coagulopathy on the basis of updated experiences and studies (<xref rid="B104" ref-type="bibr">104</xref>). The corresponding thrombus prevention and treatment options are also changing. Therefore, we include the review of clinical trials and guideline recommendations.</p>